अमूर्त

Clinical considerations for aspirin use in hospitalized COVID-19 patients

Adrienne Walker, Xiaoming Jia, Waleed Kayani

The novel Coronavirus Disease 2019 (COVID-19) pandemic has yielded significant morbidity and mortality worldwide, with thromboembolic complications that can progress to severe multi-organ dysfunction. Aspirin is a promising therapeutic option for reducing COVID-19 related thrombosis and in-hospital mortality. Given the available data, aspirin use in hospitalized COVID-19 patients is associated with decreased in-hospital mortality, especially among the elderly or those with pre-existing coronary artery disease. However, there is necessity for more data regarding the dosage, timing, and duration of therapy. This review assimilates the existing data on the association between aspirin use in hospitalized COVID-19 patients and in-hospital mortality. Overall, most recent observational studies, randomized controlled trials, and meta-analyses suggest that aspirin administration confers a protective effect in hospitalized moderate-severe COVID-19 patients. Further data will be necessary to determine the ideal dosage and time frame for administration of this medication in this clinical context.